Table 3.
US applicant awarded federally funded grant between the application year and September 2019 (N = 87)
| Model 1 | Model 2 | Model 3 | Model 4 | |||||
|---|---|---|---|---|---|---|---|---|
| b (SE) | OR (95% CI) | b (SE) | OR (95% CI) | b (SE) | OR (95% CI) | b (SE) | OR (95% CI) | |
| MT-DIRC | ||||||||
| Nonfellow (ref) | ||||||||
| Fellow | 1.2 (0.6) | 3.2 (1.1–11.0) | 1.2 (0.6) | 3.3 (1.1–11.6) | 1.1 (0.6) | 3.0 (0.99–10.2) | 1.1 (0.6) | 3.1 (0.98–11.0) |
| Timea | 0.3 (0.2) | 1.4 (0.9–2.1) | 0.4 (0.2) | 1.5 (0.9–2.4) | 0.3 (0.2) | 1.4 (0.9–2.1) | 0.40 (0.2) | 1.5 (0.96–2.4) |
| Cancer research area | ||||||||
| Treatment (ref) | ||||||||
| Survivorship | − 0.9 (0.86) | 0.4 (0.1–2.0) | − 0.8 (0.9) | 0.5 (0.1–2.6) | ||||
| Detection | − 0.8 (0.85) | 0.5 (0.1–2.4) | − 0.7 (0.9) | 0.5 (0.1–2.6) | ||||
| Prevention | − 1.1 (0.71) | 0.3 (0.1–1.3) | − 1.1 (0.7) | 0.3 (0.1–1.3) | ||||
| Previous grant funding | ||||||||
| No (ref) | ||||||||
| Yes | 0.6 (0.5) | 1.9 (0.7–5.3) | 0.6 (0.5) | 1.9 (0.7–5.7) | ||||
aTime in years from the application year to September 2019, when data was collected. Bold values are significant at p < 0.05